Opportunities for overcoming tuberculosis: Emerging targets and their inhibitors

Liu Yang,Xueping Hu,Xin Chai,Qing Ye,Jinping Pang,Dan Li,Tingjun Hou
DOI: https://doi.org/10.1016/j.drudis.2021.09.003
IF: 8.369
2022-01-01
Drug Discovery Today
Abstract:Tuberculosis (TB), an airborne infectious disease mainly caused by Mycobacterium tuberculosis (Mtb), remains a leading cause of human morbidity and mortality worldwide. Given the alarming rise of resistance to anti-TB drugs and latent TB infection (LTBI), new targets and novel bioactive compounds are urgently needed for the treatment of this disease. We provide an overview of the recent advances in anti-TB drug discovery, emphasizing several newly validated targets for which an inhibitor has been reported in the past five years. Our review presents several attractive directions that have potential for the development of next-generation therapies.
pharmacology & pharmacy
What problem does this paper attempt to address?